Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0000879169-25-000017
Filing Date
2025-01-17
Accepted
2025-01-17 15:32:49
Documents
3
Period of Report
2025-01-15

Document Format Files

Seq Description Document Type Size
1 FORM 4 wk-form4_1737145955.html 4  
1 FORM 4 wk-form4_1737145955.xml 4 3570
2 EX-24 stamoulis-incytesection1.htm EX-24 3630
3 stamoulis-incytesection1001.jpg GRAPHIC 245565
  Complete submission text file 0000879169-25-000017.txt   347272
Mailing Address 1801 AUGUSTINE CUT-OFF WILMINGTON DE 19803
Business Address 1801 AUGUSTINE CUT-OFF WILMINGTON DE 19803 3024986700
INCYTE CORP (Issuer) CIK: 0000879169 (see all company filings)

EIN.: 943136539 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 8731 Services-Commercial Physical & Biological Research
(CF Office: 08 Industrial Applications and Services)

Mailing Address C/O VERTEX PHARMACEUTICALS INCORPORATED 130 WAVERLY ST CAMBRIDGE MA 02139
Business Address
Stamoulis Christiana (Reporting) CIK: 0001502917 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-12400 | Film No.: 25538458